4D Molecular Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Daniel Giraldo from Bank of America Securities maintained a Buy rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Giraldo’s rating is based on the promising clinical data for 4D Molecular Therapeutics’ 4D-150 treatment, which has shown sustained efficacy in improving visual acuity and reducing central subfield thickness in patients with diabetic macular edema (DME). The 12-month data, expected to be presented at the ASRS, is anticipated to confirm the durability of these results, which are comparable to traditional anti-VEGF therapies. The experts consulted by Giraldo are optimistic about the potential for long-term durability and reduced treatment burden, as evidenced by the significant reduction in treatment frequency reported at 32 weeks.
Additionally, the safety profile of 4D-150 appears favorable, with low rates of inflammation and no severe adverse effects reported, which is crucial for its adoption in the market. The potential market opportunity is further supported by the expectation that 4D-150 could be used in 20-30% of DME patients, contingent on continued positive safety and efficacy outcomes. Giraldo maintains a bullish outlook on the commercial prospects of 4D-150, with a price objective of $30, reflecting confidence in the therapy’s ability to capture a significant share of the evolving treatment landscape.
According to TipRanks, Giraldo is an analyst with an average return of -6.9% and a 40.00% success rate.